XML 52 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2020
Mar. 31, 2021
Sep. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2020
Finite-lived intangible assets, net   $ 56,831         $ 113,660
2018 Aspire Purchase Agreements [Member]              
Finite-lived intangible assets, net             113,660
Finite-lived intangible assets, accumulated amortization             $ 1,477,554
Glioblastoma Multiforme Brain Cancer [Member]              
Asset impairment charges         $ 2,400,000    
IPR&D Drug Technology Platforms [Member]              
Asset impairment charges          
IPR&D Drug Technology Platforms [Member] | Ovarian Cancer [Member]              
Finite-lived intangible assets acquired   13,300,000          
EGEN Inc [Member]              
Asset impairment charges           $ 7,000,000  
Goodwill, acquisition   2,000,000          
EGEN Inc [Member] | Purchase Agreement [Member]              
Finite-lived intangible assets acquired   $ 1,600,000          
Finite-lived intangible asset, useful life   7 years          
Amortization expense   $ 56,829   $ 56,829      
Finite-lived intangible assets, net   56,831          
Finite-lived intangible assets, accumulated amortization   1,534,383          
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer [Member]              
Asset impairment charges $ 2,400,000         $ 9,400,000  
Non-cash charge     $ 2,400,000        
EGEN Inc [Member] | IPR&D Drug Technology Platforms [Member]              
Indefinite lived intangible assets   $ 24,200,000